Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
Russian army chiefs torturing and executing soldiers who refuse to fight in Ukraine, report says
30/10/2025
Juve’s tetchy Tudor period ends but recent mistakes cannot be undone | Nicky Bandini
30/10/2025
Are you in a community choir ? We would like to hear from you
30/10/2025
Virgin Media O2 teams with Musk’s Starlink to offer improved UK rural mobile coverage
30/10/2025
Can I learn to be cool – even though I am garrulous, swotty and wear no-show socks ?
30/10/2025
When the rains don’t come : how drought and endless dry seasons are changing life in Puntland – in pictures
30/10/2025